Dr. Franchimont has a background in rheumatology. Prior to her new role, she served as senior vice president and head of the multiple sclerosis and immunology development unit at Biogen.
“I am delighted to welcome Nathalie to our leadership team as Nimbus advances multiple potential breakthrough candidates into their next phase of development, including our clinical TYK2 and HPK1 inhibitors,” Nimbus CEO Jeb Keiper said in the Oct. 26 Nimbus news release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
